DEF: Senti Biosciences Seeks Stockholder Approval for Share Issuance and Equity Plan Changes

Senti Biosciences is holding a special meeting to seek stockholder approval for a share issuance related to a recent private placement and to amend its equity incentive plan.

Summary

• Senti Biosciences is holding a special meeting of stockholders on March 6, 2025, to vote on three proposals.
• The first proposal seeks approval for the issuance of common stock upon the conversion of Series A Preferred Stock and the exercise of warrants issued in a private placement in December 2024, which raised approximately $47.6 million.
• This issuance could result in a change of control and is subject to Nasdaq listing rules.
• The second proposal requests an increase of 4,300,000 shares to the 2022 Equity Incentive Plan, increase the number of shares that may be issued pursuant to incentive stock options to 4,816,434 shares and extend the plan's term by ten years.
• The third proposal is to approve an adjournment of the special meeting if there are insufficient votes for the first two proposals.
• The record date for stockholders entitled to vote at the meeting is January 21, 2025.
• The company plans to mail the proxy materials on or about January 27, 2025.
• The meeting will be held virtually at 9:00 a.m. Pacific Time.

Sentiment

Score: 4

Explanation: The document is primarily factual and procedural, but the need for shareholder approval for the share issuance and the potential for significant dilution and financial obligations if the proposal is not approved, along with the fact that the conversion price of the Series A Preferred Stock was less than the minimum price under Nasdaq rules, and the fact that the currently outstanding stock options have very little retentive value for current employees given that the weighted average exercise price of $36.36 for these stock options being so far out of the money under current market conditions, indicates a negative sentiment.

Positives

• The private placement provides the company with $47.6 million in gross proceeds.
• The proposed increase in the equity incentive plan is intended to attract, motivate, and retain employees.
• The company has designed the virtual meeting to enhance stockholder access and participation.
• The company has a clawback policy in place for awards granted under the equity incentive plan.

Negatives

• The issuance of shares upon conversion of the Series A Preferred Stock will dilute existing stockholders' ownership.
• The conversion price of the Series A Preferred Stock was less than the minimum price under Nasdaq rules.
• If the share issuance proposal is not approved, the company will be obligated to pay accruing dividends on the Series A Preferred Stock at a rate of 18% per annum.
• If the share issuance proposal is not approved, the company will be obligated to redeem the Series A Preferred Stock at three times the original purchase price plus accrued dividends.
• The currently outstanding stock options have very little retentive value for current employees given that the weighted average exercise price of $36.36 for these stock options being so far out of the money under current market conditions.

Risks

• Failure to obtain stockholder approval for the share issuance could result in significant financial obligations related to the Series A Preferred Stock.
• The potential issuance of a large number of shares could depress the market price of the company's common stock.
• The company may have difficulty retaining and motivating employees if it cannot grant stock options at competitive exercise prices.
• The company is an emerging growth company and is subject to reduced public company reporting requirements.

Future Outlook

The company anticipates that if the request to increase the size of the reserved pool under the 2022 Plan is approved by stockholders, it will be sufficient to provide equity incentives to attract, retain, and motivate employees for the foreseeable future with the automatic increase allowed under the 2022 Plan.

Management Comments

• The board of directors believes that the proposed share pool increase and related changes to the 2022 Plan are reasonable, appropriate, and in the best interests of our stockholders.
• The Compensation Committee will carefully monitor our annual net burn rate, total dilution and equity expense in order to maximize stockholder value by granting only the number of equity incentive awards that it believes are necessary and appropriate to attract, reward and retain our employees and independent directors.

Industry Context

The document reflects a common practice for biotech companies to raise capital through private placements and to use equity incentives to attract and retain talent. The need for stockholder approval for certain issuances is a standard requirement under Nasdaq listing rules.

Comparison to Industry Standards

• The use of private placements to raise capital is a common practice in the biotech industry, especially for companies that are not yet profitable.
• The terms of the Series A Preferred Stock, including the accruing dividends and liquidation preference, are typical for private financings of this type.
• The proposed increase in the equity incentive plan is consistent with the need to attract and retain talent in a competitive biotech market.
• The company's approach to equity compensation, with broad-based eligibility for high-performing employees, is a common practice in the industry.
• The company's use of a virtual meeting format is becoming increasingly common, especially for companies with a geographically dispersed shareholder base.

Related Party Transactions

• The document discloses that Kanya Rajangam, the company's President, Head of Research and Development and Chief Medical Officer, is a trustee of the Iyer Family Revocable Trust, which purchased Series A Preferred Stock and warrants.
• The document discloses that Edward Mathers, a member of the board of directors, is employed as a Partner at New Enterprise Associates, Inc., which is affiliated with New Enterprise Associates 15, L.P., which purchased Series A Preferred Stock and warrants.
• The document discloses that Bayer HealthCare LLC, which holds greater than 5% of the company's outstanding stock, purchased Series A Preferred Stock and warrants.
• The document discloses that Donald Tang, a member of the board of directors, is affiliated with Celadon Partners SPV 24, which purchased Series A Preferred Stock and warrants.
• The document discloses a consulting agreement with former director David Epstein.
• The document discloses an agreement with director James Collins to serve on the Scientific Advisory Board.
• The document discloses a purchase of equipment from Seer, Inc., where former director Omid Farokhzad is the CEO.
• The document discloses a framework agreement with GeneFab, LLC, where director Donald Tang is a principal in the parent company.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution of their ownership if the share issuance proposal is approved.
• Employees will be impacted by the changes to the equity incentive plan, which are intended to attract and retain talent.
• The company's financial position will be impacted by the proceeds from the private placement and the potential obligations related to the Series A Preferred Stock.
• The company's relationship with its investors will be impacted by the outcome of the stockholder vote on the share issuance proposal.

Next Steps

• Stockholders will vote on the proposals at the special meeting on March 6, 2025.
• The company will file a Form 8-K with the SEC to announce the voting results.
• If the share issuance proposal is approved, the company will proceed with the conversion of the Series A Preferred Stock and the exercise of warrants.
• If the equity plan amendment is approved, the company will implement the changes to the 2022 Equity Incentive Plan.

Key Dates

Keywords

stock issuance, equity incentive plan, private placement, preferred stock, warrants, Nasdaq, share dilution, stock options, corporate governance, shareholder vote